Physician profile
Steven M Domsky
NPI 1922200922
$150,558.68
in general payments reported to CMS, 2019-2025
26 companies · $40K in 2025
The $40K reported for 2025 was more than what 91% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28K · 2020: $20K · 2021: $5,659 · 2022: $9,052 · 2023: $20K · 2024: $28K · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $76K · Food and Beverage: $6,360 · Travel and Lodging: $3,727 · Consulting Fee: $1,410 · Education: $236.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $76,113.00 |
| Food and Beverage | $6,359.88 |
| Travel and Lodging | $3,726.69 |
| Consulting Fee | $1,410.00 |
| Education | $236.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $71,063.40 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Pfizer INC. | $45,198.39 | 2019-2025 | |
| Bridgebio Pharma, INC. | $15,255.16 | 2025 | Attruby |
| E.R. Squibb & Sons, L.L.C. | $10,959.72 | 2019-2025 | Camzyos, Eliquis |
| United Therapeutics Corporation | $2,947.53 | 2019-2025 | Tyvaso, Remodulin, Orenitram |
| Edwards Lifesciences Corporation | $1,188.71 | 2019 | |
| Abbott Laboratories | $899.08 | 2022-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Impulse Dynamics (USA) INC. | $533.30 | 2023-2025 | Optimizer, Optimizer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $389.14 | 2019-2025 | Jardiance |
| Abiomed | $374.27 | 2022-2025 | Impella |
| Astrazeneca Pharmaceuticals Lp | $352.00 | 2019-2025 | Wainua, Farxiga, Lokelma |
| Merck Sharp & Dohme LLC | $253.89 | 2022-2025 | Winrevair, Verquvo |
| Boston Scientific Corporation | $253.36 | 2019-2025 | Watchman Access System, General - Tachy |
| Bayer Healthcare Pharmaceuticals INC. | $225.06 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $177.84 | 2019-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Respicardia, INC. | $131.74 | 2019 | |
| Alnylam Pharmaceuticals INC. | $117.28 | 2019-2024 | Onpattro, Amvuttra |
| Cardiac Dimensions, INC. | $68.34 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $57.50 | 2019-2021 | |
| Amgen INC. | $31.68 | 2023 | Repatha |
| Daxor Corporation | $31.63 | 2025 | Bva-100 |
| Novo Nordisk INC | $23.62 | 2024 | Wegovy |
| Scpharmaceuticals INC. | $14.88 | 2025 | |
| Akcea Therapeutics, INC. | $11.16 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Domsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.